retatrutide eye side effects Effects: What Clinical Trials Tell Us Retatrutide Side Effects Research |

Arthritis Rheumatol (Hoboken N.J.) (2018) 70(5):63752

In a Phase 2b study in people with type 2 diabetes and obesity over 54 weeks, treatment with cotadutide at doses of 100-300 g daily improved some non-invasive markers of NAFLD such as transaminase levels, the FIB-4 index, fatty liver disease fibrosis score (NFS) and fatty liver index (FLI) but fatty liver disease was not assessed directly with liver biopsy

[DOI] [PMC free article] [PubMed] [Google Scholar] 46.Kopp K.O., Glotfelty E.J., Li Y., Greig N.H

For patients with type 2 diabetes and ASCVD, starting a GLP-1 RA carries a Class 1, Level of Evidence A recommendation in the most recent ESC and ACC guidelines